Search the Newsreel

bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47

bioAffinity Technologies has successfully closed a private placement, raising approximately $4 million in gross proceeds from pre-funded warrants. The placement involved 8,462,027 common shares, with each pre-funded warrant priced at $0.47 and accompanied by two additional warrants. WallachBeth Capital acted as the sole placement …

bioAffinity Technologies prices $4M private placement offering

bioAffinity Technologies (NASDAQ:BIAF) has announced a private placement offering aiming to raise approximately $4.0 million. The company will sell 8,462,027 shares of common stock or pre-funded warrants, alongside warrants to purchase up to 16,924,054 shares, to an institutional investor. The offering is expected to …

BioAtla (BCAB) turns Q2 2026 profit as cash falls and going concern risk emerges

BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary

BioAtla, Inc. reported second-quarter 2026 results, showing revenue of $6.5 million and diluted EPS of $0.27, a significant improvement from the prior year's net loss and zero revenue. The company is undergoing a strategic review to maximize shareholder value, pausing clinical development, and implementing …

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA), purchasing 214,546 shares valued at approximately $3.75 million, representing a 0.48% stake in the company. Other institutional investors like Geode Capital and Marshall Wace also increased their holdings. Despite reporting a …

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received a "Moderate Buy" consensus rating from analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $36.57, though recent targets vary from $21 to $40. The company reported a …

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA

Renaissance Technologies LLC significantly increased its stake in BioAge Labs, Inc. (NASDAQ:BIOA) by 653.2% in the first quarter, acquiring an additional 120,188 shares, bringing its total to 138,588 shares valued at approximately $2.42 million. Other institutional investors also added to their positions. Despite reporting …

bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP

bioAffinity Technologies Inc. has received notification of patent allowance in Mexico for its CyPath Lung technology, further strengthening its global intellectual property portfolio. This patent protects the use of flow cytometry and specific labeling methods for detecting lung cancer cells in sputum, expanding on …

Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com

The article reports that bioAffinity Technologies Inc. filed a Form 8K on August 7th. It briefly mentions the company's stock symbol BIAF and includes general financial market data such as indices, commodities, and shares. The content is primarily a placeholder or boilerplate for financial …

bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary

bioAffinity Technologies, Inc. (BIAF) reported its Q2 2026 financial results, with revenue increasing by 19% year-over-year to $1.51M. The company narrowed its net loss to $3.37M, and diluted loss per share improved to $(0.64). Key business highlights include significant growth in CyPath® Lung revenue …

BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BioAffinity Technologies, Inc. has released its earnings results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in sales to USD 1.51 million compared to USD 1.27 million a year ago, while reducing …

Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

BioAffinity Technologies announced its financial results for the second quarter of 2026, highlighting strong commercial growth for its CyPath® Lung diagnostic. The company reported a significant increase in test volumes and revenue compared to the previous year, driven by expanding insurance coverage and successful …

Bioatla Inc (BCAB) Stock News Today

This article provides an update on Bioatla Inc (BCAB) stock news, earnings, analyst ratings, and key developments. As of August 7th, BCAB closed at $3.460, up 3.90%. The report indicates that more news is expected soon regarding the company.

Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bioatla Inc (BCAB) has an earnings forecast score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Analysts have a consensus price target of USD 10.00 and a "Strong Buy" rating for the stock. The company's previous quarter's EPS was USD -8.18, …

bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates

bioAffinity Technologies (NASDAQ: BIAF) reported a second-quarter EPS of $-0.640, significantly beating the analyst estimate of $-2.100 by $1.46. However, the company's revenue for the quarter was $1.5M, falling short of the consensus estimate of $1.7M. The stock has experienced a significant decline over …

bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M

bioAffinity Technologies reported its Q2 2026 financial results, showing revenue of $1.51 million, an increase from $1.27 million in Q2 2025, and a net loss of $3.37 million, an improvement from $4.06 million in Q2 2025. The company's cash and cash equivalents decreased to …

BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss

BioAffinity Technologies (BIAF) reported significant growth in Q2 2026, with CyPath Lung test volume increasing by 216% and revenue by 19%. This growth was attributed to accelerated physician adoption and expanded clinical trials. Despite increased operating expenses due to commercialization efforts, the company improved …

BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for BIOAGE Labs Inc (BIOA), highlighting an earnings forecast score of 8.44 and an average price target of $12.00. Based on ratings from 9 analysts, the stock is predominantly recommended as a "Buy." Key financial expectations include an …

BIOAGE Labs Inc (BIOA) Stock News Today

A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73

This article provides a brief overview of recent analyst ratings for BioAge Labs (BIOA.US), highlighting a wide forecast range for its stock price between $21 and $73. It indicates that these ratings come from investment analysts who are evaluating the company's future performance.

BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside

BioAge Labs, Inc. (BIOA) has seen its average 12-month price target cut to $35.62 from $39.88, according to 8 analysts, yet this still implies a significant 224% potential upside based on its closing price. Despite the target reduction, the consensus rating from 9 analysts …

BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary

BioAge Labs, Inc. reported its second-quarter 2026 results, showing flat revenue year-over-year at $2.45 million and a wider net loss, with a diluted loss per share of $(0.58). Despite the financial performance, the company highlighted positive clinical progress for BGE-102, advancement in its QUELL-CV …

BioAge Labs, Inc. (BIOA) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of BioAge Labs, Inc. (BIOA) stock, including its current price, historical data, company profile, and financial performance. It highlights key financial metrics, analyst ratings, and recent stock performance compared to the S&P 500, detailing the company's …

BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development

BioAge Labs announced its Q2 2026 results, reporting a net loss of $26.1 million, but also significant progress in its clinical trials. The company dosed the first patient in its QUELL-CV Phase 2 trial for BGE-102, targeting inflammation and cardiometabolic biomarkers, with topline data …

BioAge Labs Q2 NetLoss Expands; Expects QUELL-CV Phase 2 Results Of BGE-102 In H2 2026

(RTTNews) - BioAge Labs, Inc. (BIOA), a clinical-stage biopharmaceutical company, reported second-quarter financial results reflecting a wider net loss despite a marginal increase in collaboration-based revenue. BioAge develops therapeutic product candidates for cardiometabolic diseases. BioAge's lead product candidate, BGE-102, is a potent, orally bioavailable, …

BCAB Q2'26 Earnings: EPS estimate is (8.50) USD

BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6th. Analysts estimate revenue to be $0 with an earnings per share (EPS) of ($8.50). This report provides a quick overview of estimated vs. reported EPS for previous quarters.

BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary

BioAge Labs, Inc. has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters and published on TradingView, provides an overview of the company's financial performance. Readers are encouraged to access the full article on TradingView for …

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs reported its second-quarter 2026 financial results, highlighting progress in its clinical development programs for BGE-102, an oral NLRP3 inhibitor. The company announced the first participant dosed in its QUELL-CV Phase 2 trial for obesity and inflammation, with topline data expected in late …

BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances

BioAge Labs reported a net loss of $48.4 million for the first half of 2026 but holds a strong cash position of $381.3 million, expected to fund operations through 2029. The company is advancing its lead candidate BGE-102, an NLRP3 inhibitor, with positive Phase …

BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned

BioAge Labs reported a Q2 2026 net loss of $26.1 million on collaboration revenue of $2.4 million, with increased R&D expenses driven by its BGE-102 program. The company has dosed the first participant in its Phase 2 QUELL-CV trial for obesity with inflammation, expecting …

Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G

This article provides financial information for BioAge Labs, Inc. (SWB:Y7G), specifically focusing on its price-to-earnings forward metric. The content includes a brief mention of the period, value, and change associated with this financial indicator.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates